Simplified Chinese
Reposted: Kangtai Biological attends the 2026 Vaccine and Health Conference; several innovative vaccine candidates have drawn significant attention from the industry.
Release date:
2026-04-22
Author:
Source:
Abstract
Recently, the 2026 Vaccine and Health Conference, hosted by the Chinese Society of Preventive Medicine, was held in Changsha, Hunan Province. The conference focused on key topics such as cutting-edge vaccine technologies, the current state of disease prevention and control, and the development of next-generation vaccines, bringing together industry experts to share the latest research findings, build consensus on industry development, and support advancements in China’s vaccine R&D, clinical application, and vaccination service delivery.
In a special presentation on “Advances in Polysaccharide–Protein Conjugation Technologies and Their Vaccine Applications,” industry experts noted that, compared with various carrier-protein vaccines, The bivalent PCV13 (TT/DT) demonstrates significant advantages: it not only boasts five-year data on robust immune persistence in the Chinese population, but it is also currently the only vaccine listed in the Chinese Pharmacopoeia. 13-valent pneumococcal conjugate vaccine 。
Researcher, Biological Products Branch, Chinese Society of Preventive Medicine, Kangtai Biological During his presentation on “R&D Progress in Multivalent Vaccines,” Director and Vice President Liu Jiankai stated: “Multivalent vaccines are bound to become the future trend in vaccine development, potentially even representing the ultimate form of vaccination: a single dose that prevents multiple diseases.” Combination vaccines can reduce the number of injections, significantly boosting vaccination rates and immunization coverage, making them a critical tool for building a national immune barrier. At the same time, they lower vaccine storage, transportation, and management costs, creating win‑win outcomes for all stakeholders.
In light of the current status of rabies prevention and control, Li Hu, an associate chief physician at Beijing Luhe Hospital affiliated with Capital Medical University, presented the latest epidemiological data in his report: in 2025, China reported 248 cases of rabies, a 46% increase compared to 2024, marking the highest number of cases in the past six years. He also clearly outlined standardized vaccination management requirements for rabies‑prevention clinics: in principle, such clinics must stock at least two different types of rabies vaccines; it is recommended to simultaneously maintain vaccines with distinct immunization schedules and derived from different cell substrates. The report emphasizes addressing key challenges—such as vaccine switching and seamless protocol transitions—to ensure complete and effective全程 (full-course) immunization.
Kangtai Biological’s lyophilized human rabies vaccine, approved for marketing in 2023, is the first in China to receive approval under both the “2-1-1” and… Five-needle method Human diploid cell rabies vaccine with two immunization schedules.
The experts attending the meeting also delivered a detailed report on “the application of vaccines in eliminating the public health burden of hepatitis B,” emphasizing that “at the national level, vaccination against hepatitis B is encouraged to prevent liver cancer, and efforts to increase hepatitis B vaccination coverage among adults at high risk of infection are being strengthened.” Currently, China has achieved remarkable results in preventing and controlling hepatitis B among children, while the use of hepatitis B vaccines for adults is being rapidly expanded. Notably, in 2010, Kangtai Biological launched its product after introducing the complete set of production technologies from Merck in the United States. World’s first 60 μg hepatitis B vaccine It has yielded significant results in both the national “12th Five-Year Plan” and “13th Five-Year Plan” research projects on major infectious diseases, demonstrating favorable efficacy across diverse populations, including healthy adults, non-responders, and individuals with chronic conditions.
This conference has forged industry-wide consensus and facilitated the exchange of cutting-edge technologies, thereby advancing China’s vaccine research and development, clinical application, and vaccination service quality, and injecting momentum into safeguarding public health and building a global community of health for all.
As a leading enterprise in China’s vaccine industry, Kangtai Biological boasts industry‑leading sales scale and R&D capabilities, with its proprietary product revenues ranking among the highest in the sector. Over the past five years, the company has consistently maintained the top position in the industry for the total number of approved products, underscoring its exceptional capacity for R&D translation and commercialization.
The company adheres to an R&D strategy of “New in China, New Globally,” with its pipeline boasting the highest overall value in the industry; domestically, it leads in R&D progress. Pentavalent vaccine It is poised to disrupt the monopoly of imported products; the Klebsiella pneumoniae vaccine and the RSV/hMPV combination vaccine both hold the potential to become first-in-class products.
In implementing its internationalization strategy, the company adopts a dual‑pronged “attracting investment and going global” approach. As one of the most internationally advanced players in China’s vaccine industry, Kangtai has undertaken all vaccine technology transfer projects for major international biopharmaceutical companies operating in the Chinese market. In recent years, the company’s innovative products have initiated registration processes in numerous densely populated countries along the Belt and Road Initiative, with its future strategic footprint poised to reach nearly half of the world’s newborn population.
Looking ahead, Kangtai Biological will accelerate its strategic shift from disease prevention to therapeutics, focusing on cutting-edge global technological innovation and industrialization. The company is committed to becoming a leading biotechnology enterprise with international influence, continuously advancing the sustainable development of global public health.
Recommended Reading
Batch Release Status of the Company’s Products in 2026
2026-07-23
2026-07-15
2026-07-09
Contact Information
Customer Service Hotline
4001899806
Phone number
010-59613600
Official Website
Company Address
No. 35 Simiao Road and No. 25 Tianfu Street, Daxing Biomedical Industry Base, Zhongguancun Science Park, Daxing District, Beijing
WeChat Official Account